High dose cotrimoxazole treatment in patients with severe COVID-19: A randomised controlled trial
DOI:
https://doi.org/10.3329/bsmmuj.v17i3.74383Keywords:
cotrimoxazole, severe COVID, randomised controlled trial, BangladeshAbstract
Background: Cotrimoxazole for severe COVID-19 may have a better prognosis because of its antibacterial, immunomodulatory, and anti-inflammatory activities. We examined the efficacy of high-dose cotrimoxazole therapy in terms of duration of hospital stays and reduction in mortality in severe COVID-19 infections.
Methods: From May to November 2021, we conducted a double blind randomised controlled trial with two parallel groups in the COVID units of Bangabandhu Sheikh Mujib Medical University and Anwar Khan Modern Medical College Hospital, Dhaka. One group received standard therapy in addition to an oral dose of 960 mg of cotrimoxazole twice daily for 7 days (intervention group), while the other group received standard treatment and a placebo (standard group). Pre-protocol analysis was done.
Results: A total of 188 patients were enrolled, but 166 completed the study. Of them, 93 were in the intervention group and 73 were in standard group. The mean ages of the groups were similar (intervention, 56.2 and standard, 59.2 years) (P=0.10). The mortality at 28 days between groups was also similar (11.8% in the intervention group and 15.0% in the standard group) (P=0.56). The hospital stay was 13.7 days for the intervention group and 13.5 days for the standard group (P=0.86). However, the reduction in C-reactive protein was statistically significant in the intervention group, with a mean decline of 23.6 mg/L (95% confidence interval, 0.5–46.7 mg/L).
Conclusion: High-dose cotrimoxazole did not benefit in shortening in-hospital stay or reducing mortality at day 28 in patients with severe COVID-19. However, the decline in the C-reactive protein level was significant, necessitating further research.
Downloads
268
71 Review report
15
References
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113. DOI: https://doi.org/10.1001/jama.2021.2336.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Feb 15;395(10223):496. DOI: https://doi.org/10.1016/S0140-6736(20)30252-X.
Li L, Chen K, Xiang Y, Yoshimura T, Su S, Zhu J, Bian XW, Wang JM. New development in studies of formyl-peptide receptors: critical roles in host defense. J Leukoc Biol. 2016 Mar;99(3):425-435. DOI: https://doi.org/10.1189/jlb.2RI0815-354RR.
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Daßler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020 Jun 1;217(6):e20200652. DOI: https://doi.org/10.1084/jem.20200652.
Siddiqui K, Das MK, Bandyopadhyay A. Cotrimoxazole in the Domiciliary Management of Clinically Diagnosed Severe COVID-19: A Case Series. Journal of Indian Medical Association. 2020 Oct 118(10):34-38. URL: https://www.ima-india.org/ima/left-side-bar.php?pid=347.
Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ. Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation. Sci Transl Med. 2019 Apr 3;11(486):eaav0537. DOI: https://doi.org/10.1126/scitranslmed.aav0537.
Varney VA, Smith B, Quirke G, Parnell H, Ratnatheepan S, Bansal AS, Nicholas A. The effects of oral cotrimoxazole upon neutrophil and monocyte activation in patients with pulmonary fibrosis and healthy controls; does this relate to its action in idiopathic pulmonary fibrosis? In: Cellular insights into lung injury repair. BMJ Publishing Group Ltd and British Thoracic Society; 2017. p A109. DOI: https://doi.org/10.1136/thoraxjnl-2017-210983.191.
Ohtake T, Kobayashi S, Honjou Y, Shirai T, Takayanagi S, Tohyama K, Tokura Y, Kimura M. Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. Intern Med. 2001 Jul;40(7):666-670. DOI: https://doi.org/10.2169/internalmedicine.40.666.
Singh S, John T, Kumar P, Quadery SR. The impact of high dose oral cotrimoxazole in patients with COVID-19 with hypoxic respiratory failure requiring non-invasive ventilation: A Case Control Study. MedRxiv. 2021 Jan 15. DOI: https://doi.org/10.1101/2021.01.14.21249803.
Quadery SR, John T, Sinha P, Bhattacharjee M, Bose S, Ghosh UC, Bhattacharyya B, Tripathi SK. Cotrimoxazole in hospitalised patients with severe COVID-19 – interim results from the CoTroxCov study. 1001 - Respiratory infections and bronchiectasis. 2022 Sep 4;1544. DOI: http://dx.doi.org/10.1183/13993003.congress-2022.1544.
Quadery RS, John T, Samuel T, Ramanna S, Chattopadhyay G, Malapanjudi C, Sodha A, Lawrence R, Dutta S, Varney AV. Improved Recovery and Survival with Trimethoprim or Cotrimoxazole in Patients with Severe COVID-19: A Retrospective Analysis. Journal of Virology Research & Reports. 2020 Dec 30;1–6. DOI: https://doi.org/10.47363/JVRR/2020(1)118.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Humayra Jesmin, Syed Rehan Quadery, Tania Tofail, Hasinatul Zannat, Chowdhury Adnan Sami, Shohael Mahmud Arafat
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
